Pharmaxis Ltd

Press Releases


You will need the Adobe Acrobat Reader 7.0 to view the PDF.
If you do not have any of the above, please download "Acrobat Reader".

  • 2009-June-30
  • Pharmaxis Closes Share Purchase Plan (in PDF)
  • 2009-June-16
  • Phase 3 Cystic Fibrosis Trial Results Presented at European Conference (in PDF)
  • 2009-June-4
  • Pharmaxis Announces Placement of $47 Million and Share Purchase Plan (in PDF)
  • 2009-May-14
  • U.S. FDA Accepts AridolTM New Drug Application for Review (in PDF)
  • 2009-May-4
  • Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial (in PDF)
  • 2009-April-7
  • New Pharmaxis Board Appointment (in PDF)
  • 2009-April-6
  • Pharmaxis Investor Conference Call (in PDF)
  • 2009-April-1
  • Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis (in PDF)
  • 2009-March-11
  • Pharmaxis Appoints French Distributor for AridolTM (in PDF)
  • 2009-March-2
  • Pharmaxis Announces New Drug Application Submission for AridolTM (in PDF)
  • 2009-February-17
  • Pharmaxis Builds Senior Management Team (in PDF)
  • 2009-January-27
  • Pharmaxis Investor Conference Call (in PDF)
  • 2008
  • 2008 Press Releases
  • 2007
  • 2007 Press Releases
  • 2006
  • 2006 Press Releases
  • 2005
  • 2005 Press Releases
  • 2004
  • 2004 Press Releases


  • Company's Index
  • irasia.com

  • © Copyright 1996-2009 irasia.com Ltd. All rights reserved.
    DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any information provided on this website. Under no circumstances shall irasia.com Ltd be liable for damages resulting from the use of the information provided on this website.
    TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited.
    TERMS OF USE: Please read the Terms of Use governing the use of our website.